cetuximab biosimilar
/ CinnaGen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 05, 2023
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
(clinicaltrials.gov)
- P3 | N=234 | Recruiting | Sponsor: Cinnagen | Unknown status ➔ Recruiting | Trial completion date: Feb 2020 ➔ Feb 2026 | Trial primary completion date: Nov 2019 ➔ Nov 2025
Enrollment open • Metastases • Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • EGFR • RAS
1 to 1
Of
1
Go to page
1